{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:55:14Z","timestamp":1781636114984,"version":"3.54.5"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Long-term benzodiazepine (BZD) use is associated with adverse clinical outcomes and increased healthcare utilization. Although deprescription programs aim to reduce these risks, the net economic impact of BZD discontinuation\u2014particularly in terms of healthcare resource use\u2014remains unclear. This study aimed to evaluate the cost-utility of BZD deprescription intervention in primary care, assessing its impact on direct healthcare costs, service utilization, and quality-adjusted life years (QALYs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study using data from 333 patients enrolled in the BenzoStopJuntos deprescription program in Andalusia, Spain. Participants were classified according to BZD status at six-month follow-up: continuation vs. discontinuation. Healthcare resource use (primary care, hospital specialist consultations, primary care emergency, and hospital emergency visits) was extracted from routine electronic health records and monetized using standardized national tariffs (2024 euros). Health outcomes were estimated using the COOP\/WONCA charts, from which utility scores and QALYs were derived. We conducted a cost-utility analysis (CUA) from the public payer perspective and calculated the incremental cost-effectiveness ratio (ICER). Probabilistic sensitivity analysis (PSA) was performed using Monte Carlo simulations. Covariate-adjusted Poisson regression models were used to analyze the association between BZD status and healthcare utilization. Subgroup analyses were conducted by comorbidity level (Charlson Comorbidity Index) and sex.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 333 participants, 45.6% discontinued BZD use at follow-up. The discontinuation group incurred lower mean total healthcare costs (\u20ac753.2 vs. \u20ac826.6), with a non-significant difference of \u2013\u20ac73.4, and higher mean QALYs, resulting in an incremental QALY gain of 0.033. The ICER was \u2013\u20ac2,185 per QALY, indicating that deprescription was a dominant strategy. Adjusted Poisson models showed a significant 45% reduction in primary care emergency visits in the discontinuation group (IRR\u2009=\u20090.55, 95% CI: 0.37\u20130.82;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003), with no significant differences in routine primary care, hospital specialist consultations, or hospital emergency visits. PSA confirmed the robustness of these findings, with the majority of simulations in the southeast quadrant of the cost-effectiveness plane. Subgroup analyses showed consistent cost-effectiveness, with greater dominance observed in participants with low to moderate comorbidity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>BZD deprescription through a structured primary care intervention is a cost-effective and clinically safe strategy. It does not result in increased short-term healthcare utilization and may reduce emergency care demands. These findings support the integration of deprescription protocols into routine clinical practice and the expansion of similar interventions in public health systems.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov NCT06209827. 01\/12\/21<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12913-026-14149-2","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T05:35:39Z","timestamp":1771306539000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-utility analysis of benzodiazepine deprescription in primary care: a cohort study"],"prefix":"10.1186","volume":"26","author":[{"given":"Ingrid","family":"Ferrer L\u00f3pez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"\u0160pac\u00edrov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Olry de Labry-Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Gutierrez-Valencia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Florencio Sayago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Martinez Celdran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonia","family":"Sumariva Bernal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Berm\u00fadez-Tamayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"issue":"5","key":"14149_CR1","doi-asserted-by":"publisher","first-page":"152","DOI":"10.18773\/austprescr.2015.055","volume":"38","author":"J Brett","year":"2015","unstructured":"Brett J, Murnion B. Management of benzodiazepine misuse and dependence. Aust Prescr. 2015 Oct 1;38(5):152\u2013155","journal-title":"Aust Prescr"},{"issue":"5","key":"14149_CR2","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1093\/fampra\/cmab017","volume":"38","author":"PR De Souza Ribeiro","year":"2021","unstructured":"De Souza Ribeiro PR, Schlindwein AD. Benzodiazepine deprescription strategies in chronic users: a systematic review. Fam Pract. 2021;38(5):684\u2013693","journal-title":"Fam Pract"},{"issue":"2","key":"14149_CR3","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3325\/cmj.2024.65.146","volume":"65","author":"AK Kozole Smid","year":"2024","unstructured":"Kozole Smid AK, Mlakar A, \u0160tukovnik V. Toxicity of benzodiazepines in the treatment of insomnia disorders in older adults: a systematic literature review. Croat Med J. 2024;65(2):146\u2013155","journal-title":"Croat Med J"},{"key":"14149_CR4","doi-asserted-by":"crossref","unstructured":"Dodds TJ. Prescribed benzodiazepines and suicide risk: a review of the literature. Prim Care Companion CNS Disord [Internet]. 2017;19(2). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28257172\/. cited 2026 Jan 15","DOI":"10.4088\/PCC.16r02037"},{"key":"14149_CR5","doi-asserted-by":"crossref","unstructured":"Lader M. Benzodiazepine harm: how can it be reduced? Br J Clin Pharmacol [Internet]. 2014 Feb;77(2):295\u2013301. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/22882333\/. cited 2026 Jan 15","DOI":"10.1111\/j.1365-2125.2012.04418.x"},{"key":"14149_CR6","doi-asserted-by":"crossref","unstructured":"Orriols L, Philip P, Moore N, Castot A, Gadegbeku B, Delorme B, et al. Benzodiazepine-like hypnotics and the associated risk of road traffic accidents. Clin Pharmacol Ther [Internet]. 2011;89(4):595\u2013601. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/21368756\/. cited 2026 Jan 15","DOI":"10.1038\/clpt.2011.3"},{"issue":"8","key":"14149_CR7","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.jamda.2018.02.013","volume":"19","author":"B Appelhof","year":"2018","unstructured":"Appelhof B, Bakker C, van Duinen-van den IJssel JCL, Zwijsen SA, Smalbrugge M, Verhey FRJ, et al. Process evaluation of an intervention for the Management of neuropsychiatric symptoms in young-onset dementia. J Am Med Dir Assoc. 2018;19(8):663\u2013671","journal-title":"J Am Med Dir Assoc"},{"issue":"5","key":"14149_CR8","first-page":"339","volume":"64","author":"K Pottie","year":"2018","unstructured":"Pottie K, Thompson W, Davies S, Grenier J, Sadowski CA, Welch V, et al. Deprescribing benzodiazepine receptor agonists. Can Fam Physician. 2018;64(5):339\u2013351","journal-title":"Can Fam Physician"},{"key":"14149_CR9","doi-asserted-by":"crossref","unstructured":"L\u00f3pez IF, Labry-Lima AO de, Guti\u00e9rrez-Valencia A, Berm\u00fadez EG, Mart\u00edn FA, Morente AGD, et al. Risk perception, attitudes, and quality of life in a multicomponent benzodiazepine deprescription strategy. Explor Res Clin Soc Pharm [Internet]. 2025 Dec;20:100666. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12547013\/. cited 2025 Nov 7","DOI":"10.1016\/j.rcsop.2025.100666"},{"issue":"5","key":"14149_CR10","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1001\/jamainternmed.2015.0324","volume":"175","author":"I Scott","year":"2015","unstructured":"Scott I, Hilmer S, Reeve E, Potter K, Le Couteur D, Rigby D, et al. Reducing inappropriate polypharmacy. The process of deprescribing. JAMA Intern Med. 2015;175(5):827\u2013834","journal-title":"JAMA Intern Med"},{"issue":"6","key":"14149_CR11","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1192\/bjp.bp.113.134650","volume":"204","author":"C Vicens","year":"2014","unstructured":"Vicens C, Bejarano F, Sempere E, Mateu C, Fiol F, Socias I, et al. Comparative efficacy of two interventions to discontinue long-term benzodiazepine use: cluster randomised controlled trial in primary care. Br J Psychiatry. 2014;204(6):471\u2013479","journal-title":"Br J Psychiatry"},{"issue":"6","key":"14149_CR12","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1001\/jamainternmed.2014.949","volume":"174","author":"C Tannenbaum","year":"2014","unstructured":"Tannenbaum C, Martin P, Tamblyn R, Benedetti A, Ahmed S. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education. The EMPOWER cluster randomized trial. JAMA Intern Med. 2014;174(6):890\u2013898","journal-title":"JAMA Intern Med"},{"key":"14149_CR13","unstructured":"Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults NICE guideline. 2022. Available from: https:\/\/doi.org\/www.nice.org.uk\/guidance\/ng215. cited 2024 Oct 2"},{"key":"14149_CR14","doi-asserted-by":"crossref","unstructured":"Soni A, Thiyagarajan A, Reeve J. Feasibility and effectiveness of deprescribing benzodiazepines and Z-drugs: systematic review and meta-analysis. Addiction (Abingdon, England) [Internet]. 2023 Jan 1;118(1):7\u201316. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35815384\/. cited 2026 Jan 13","DOI":"10.1111\/add.15997"},{"key":"14149_CR15","doi-asserted-by":"crossref","unstructured":"Darker CD, Sweeney BP, Barry JM, Farrell MF, Donnelly-Swift E. Psychosocial interventions for benzodiazepine harmful use, abuse or dependence. Cochrane Database Syst Rev. 2015 May 11;2015(5): CD009652","DOI":"10.1002\/14651858.CD009652.pub2"},{"key":"14149_CR16","doi-asserted-by":"crossref","unstructured":"Allary A, Proulx-Tremblay V, B\u00e9langer C, Hudon C, O\u2019Connor K, Roberge P, et al. Long-term effects of benzodiazepine discontinuation among older adults: potential improvements on depressive symptoms. Aging Ment Health [Internet]. 2024;28(12):1625\u20131633. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/38952209\/. cited 2026 Jan 13","DOI":"10.1080\/13607863.2024.2372473"},{"key":"14149_CR17","doi-asserted-by":"crossref","unstructured":"Vicens C, Sempere E, Bejarano F, Socias I, Mateu C, Fiol F, et al. Efficacy of two interventions on the discontinuation of benzodiazepines in long-term users: 36-month follow-up of a cluster randomised trial in primary care. Br J Gen Pract [Internet]. 2016 Feb 1;66(643):e85\u201391. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26823269\/. cited 2026 Jan 13","DOI":"10.3399\/bjgp16X683485"},{"key":"14149_CR18","doi-asserted-by":"crossref","unstructured":"Croke A, Cardwell K, Clyne B, Moriarty F, McCullagh L, Smith SM. The effectiveness and cost of integrating pharmacists within general practice to optimize prescribing and health outcomes in primary care patients with polypharmacy: a systematic review. BMC Primary Care. 2023 Dec 1;24(1)","DOI":"10.1186\/s12875-022-01952-z"},{"key":"14149_CR19","doi-asserted-by":"crossref","unstructured":"Ingvarsson S, Hasson H, von Thiele Schwarz U, Nilsen P, Powell BJ, Lindberg C, et al. Strategies for de-implementation of low-value care-a scoping review. Implementation Sci. 2022 Dec 1;17(1)","DOI":"10.1186\/s13012-022-01247-y"},{"issue":"4","key":"14149_CR20","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/pcn.13195","volume":"75","author":"M Takeshima","year":"2021","unstructured":"Takeshima M, Otsubo T, Funada D, Murakami M, Usami T, Maeda Y, et al. Does cognitive behavioral therapy for anxiety disorders assist the discontinuation of benzodiazepines among patients with anxiety disorders? A systematic review and meta-analysis. Psychiatry Clin Neurosci. 2021 Apr 1;75(4):119","journal-title":"Psychiatry Clin Neurosci"},{"key":"14149_CR21","doi-asserted-by":"crossref","unstructured":"Shapoval V, de Saint Hubert M, Evrard P, Sibille FX, Aubert CE, Bolt L, et al. Barriers to deprescribing benzodiazepines in older adults in a survey of European Physicians. JAMA Netw Open. 2025 Mar;8(3):e2459883","DOI":"10.1001\/jamanetworkopen.2024.59883"},{"issue":"1","key":"14149_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12889-020-08984-z","volume":"20","author":"F Torres-Bondia","year":"2020","unstructured":"Torres-Bondia F, De Batlle J, Galv\u00e1n L, Buti M, Barb\u00e9 F, Pin\u00f5l-Ripoll G. Trends in the consumption rates of benzodiazepines and benzodiazepine-related drugs in the health region of Lleida from 2002 to 2015. BMC Public Health. 2020 Jun 1;20(1):1\u20139","journal-title":"BMC Public Health"},{"issue":"5","key":"14149_CR23","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u2013383","journal-title":"J Chronic Dis"},{"key":"14149_CR24","doi-asserted-by":"crossref","unstructured":"V\u00e1zquez Canales L de M, Frutos Fern\u00e1ndez M. La prevenci\u00f3n cuaternaria en el uso de benzodiacepinas y c\u00f3mo deprescribirlas. Atenci\u00f3n Primaria Pr\u00e1ctica [Internet]. 2023 Oct 1;5(4):100183. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2605073023000172. cited 2026 Jan 15","DOI":"10.1016\/j.appr.2023.100183"},{"key":"14149_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40545-017-0128-4","volume":"11","author":"MAF Garcia","year":"2018","unstructured":"Garcia MAF, Olry de Labry Lima A, Ferrer Lopez I, Bermudez-Tamayo C. Analysis of changes in trends in the consumption rates of benzodiazepines and benzodiazepine-related drugs. J Pharm Policy Pract. 2018;11:1","journal-title":"J Pharm Policy Pract"},{"key":"14149_CR26","unstructured":"L\u00f3pez IF, Berm\u00fadez EG, Mart\u00edn FA, Garc\u00eda-Delgado Morente A, Murillo Fern\u00e1ndez MD, Ca\u00f1ete YS, et al. Effectiveness at long-term of a multidisciplinary intervention in the reduction of overuse of benzodiazepine prescriptions: a cluster controlled trial. Res Soc Administrative Pharm. 2025 Mar 22"},{"issue":"4","key":"14149_CR27","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.gaceta.2018.11.005","volume":"33","author":"C Berm\u00fadez-Tamayo","year":"2019","unstructured":"Berm\u00fadez-Tamayo C, Olry de Labry-Lima A, Garc\u00eda-Moch\u00f3n L, Bermudez-Tamayo C, Olry de Labry-Lima A, Garcia-Mochon L, et al. Deimplementation of low-value clinical activities. From the evidence, through consensus, to a change in practices. Gac Sanit. 2019 Jul;33(4):307\u2013309","journal-title":"Gac Sanit"},{"key":"14149_CR28","doi-asserted-by":"crossref","unstructured":"Marquina-M\u00e1rquez A, Olry-De Labry-Lima A, Berm\u00fadez-Tamayo C, Ferrer L\u00f3pez I, Marcos-Marcos J. Identifying barriers and enablers for benzodiazepine (de)prescription: a qualitative study with patients and healthcare professionals. An Sist Sanit Navar. 2022 May 1;45(2)","DOI":"10.23938\/ASSN.1005"},{"issue":"2","key":"14149_CR29","first-page":"75","volume":"24","author":"Liz\u00e1n Tudela","year":"1999","unstructured":"Liz\u00e1n Tudela, Reig Ferrer A. Cross cultural adaptation of a health related quality of life measurement: the Spanish version of the COOP\/WONCA cartoons. Aten Primaria. 1999 Jun;24(2):75\u201382","journal-title":"Aten Primaria"},{"key":"14149_CR30","doi-asserted-by":"crossref","unstructured":"Sentandreu-Ma\u00f1\u00f3 T, Garc\u00eda-Moll\u00e1 A, Oltra Ferr\u00fas I, Tom\u00e1s JM, Salom Terr\u00e1dez JR. Measuring quality of life in stroke survivors: validity and reliability of the Spanish COOP\/WONCA scale. Medicina (Kaunas). 2025 May;61(5)","DOI":"10.3390\/medicina61050878"},{"key":"14149_CR31","doi-asserted-by":"crossref","unstructured":"Brazier JE, Yang Y, Tsuchiya A, Rowen DL. A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ [Internet]. 2010 Apr;11(2):215\u2013225. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/19585162\/. cited 2026 Jan 15","DOI":"10.1007\/s10198-009-0168-z"},{"key":"14149_CR32","doi-asserted-by":"crossref","unstructured":"Wailoo AJ, Hernandez-Alava M, Manca A, Mejia A, Ray J, Crawford B, et al. Mapping to estimate health-state utility from non-preference-based outcome measures: an ISPOR good practices for outcomes Research task force report. Value Health [Internet]. 2017 Jan 1;20(1):18\u201327. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28212961\/. cited 2026 Jan 15","DOI":"10.1016\/j.jval.2016.11.006"},{"key":"14149_CR33","unstructured":"Bolet\u00edn Oficial de la Junta de Andaluc\u00eda n\u00b0210. Orden de 14 de octubre de 2005, por la que se fijan los precios p\u00fablicos de los servicios sanitarios prestados por Centros dependientes del Sistema Sanitario P\u00fablico de Andaluc\u00eda. Portal de la Junta de Andaluc\u00eda. Sevilla; 2005"},{"key":"14149_CR34","unstructured":"Bolet\u00edn Oficial de la Junta de Andaluc\u00eda no 92. Orden de 8 de mayo, por la que se modifica la Orden de 14 de octubre de 2005, por la que se fijan los precios p\u00fablicos de los servicios prestados por centros dependientes del Sistema Sanitario P\u00fablico de And. Sevilla; 2018"},{"key":"14149_CR35","unstructured":"Instituto Nacional de Estad\u00edstica. C\u00e1lculo de variaciones del Indice de Precios de Consumo"},{"key":"14149_CR36","doi-asserted-by":"crossref","unstructured":"H\u00fcrlimann O, Alers D, Hauri N, Leist P, Schneider C, Bolt L, et al. Barriers, facilitators and needs to deprescribe benzodiazepines and other sedatives in older adults: a mixed methods study of primary care provider perspectives. BMC Geriatr. 2024 Dec 1;24(1)","DOI":"10.1186\/s12877-024-05027-9"},{"key":"14149_CR37","doi-asserted-by":"crossref","unstructured":"Burke KC, Meek WJ, Krych R, Nisbet R, Burke JD. Medical services use by patients before and after detoxification from benzodiazepine dependence. Internet. 1995;46(2):157\u2013160. Available from: https:\/\/doi.org\/\/doi\/pdf\/10.1176\/ps.46.2.157?download=true. cited 2025 Jul 15","DOI":"10.1176\/ps.46.2.157"},{"key":"14149_CR38","doi-asserted-by":"publisher","first-page":"33","DOI":"10.12688\/hrbopenres.13049.1","volume":"3","author":"D Tr\u00e9pel","year":"2020","unstructured":"Tr\u00e9pel D, Ali S, Gilbody S, Leiva A, Mcmillan D, Bejarano F, et al. Cost-effectiveness of brief structured interventions to discontinue long-term benzodiazepine use: an economic analysis alongside a randomised controlled trial. HRB Open Res. 2020;3:33. 2020 Jun 3; 3, 33","journal-title":"HRB Open Res"},{"issue":"1","key":"14149_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2296-13-111","volume":"13","author":"BJ Kollen","year":"2012","unstructured":"Kollen BJ, Van Der Veen WJ, Groenhof F, Donker GA, Van Der Meer K. Discontinuation of reimbursement of benzodiazepines in the Netherlands: does it make a difference? BMC Fam Pract. 2012 Nov 21;13(1):1\u20137","journal-title":"BMC Fam Pract"},{"key":"14149_CR40","doi-asserted-by":"crossref","unstructured":"Burke KC, Meek WJ, Krych R, Nisbet R, Burke JD. Medical services use by patients before and after detoxification from benzodiazepine dependence. 1995;46(2):157\u2013160","DOI":"10.1176\/ps.46.2.157"},{"key":"14149_CR41","doi-asserted-by":"crossref","unstructured":"de Gier NAH, Gorgels WJMJ, Lucassen PLBJ, Oude Voshaar R, Mulder J, Zitman F. Discontinuation of long-term benzodiazepine use: 10-year follow-up. Fam Pract. 2011","DOI":"10.1093\/fampra\/cmq113"},{"key":"14149_CR42","doi-asserted-by":"crossref","unstructured":"Reeve E, Shakib S, Hendrix I, Roberts MS, Wiese MD. Review of deprescribing processes and development of an evidence-based, deprescribing process. 2014","DOI":"10.1111\/bcp.12386"},{"issue":"4","key":"14149_CR43","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1080\/16066350801900297","volume":"16","author":"C Godfrey","year":"2008","unstructured":"Godfrey C, Heather N, Bowie A, Brodie J, Parrott S, Ashton H, et al. Randomised controlled trial of two brief interventions against long-term benzodiazepine use: cost-effectiveness. Addict Res Theory. 2008 Aug;16(4):309\u2013317","journal-title":"Addict Res Theory"},{"issue":"6","key":"14149_CR44","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s40266-023-01029-1","volume":"40","author":"FX Sibille","year":"2023","unstructured":"Sibille FX, de Saint-Hubert M, Henrard S, Aubert CE, Goto NA, Jennings E, et al. Benzodiazepine receptor agonists use and cessation among multimorbid older adults with polypharmacy: secondary analysis from the OPERAM trial. Drugs Aging. 2023 Jun 1;40(6):551\u2013561","journal-title":"Drugs Aging"},{"issue":"1","key":"14149_CR45","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/1745-6215-14-80","volume":"14","author":"P Martin","year":"2013","unstructured":"Martin P, Tamblyn R, Ahmed S, Tannenbaum C. An educational intervention to reduce the use of potentially inappropriate medications among older adults (EMPOWER study): protocol for a cluster randomized trial. Trials. 2013 Dec 20;14(1):80","journal-title":"Trials"},{"issue":"1","key":"14149_CR46","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12875-020-01166-1","volume":"21","author":"O de Labry Lima A","year":"2020","unstructured":"Olry de Labry Lima A, Marcos Marcos J, Marquina Marquez A, Gonz\u00e1lez Vera M de L\u00c1, Matas Hoces A, Berm\u00fadez Tamayo. Evidence for deprescription in primary care through an umbrella review. BMC Fam Pract. 2020 Jun;21(1):100","journal-title":"BMC Fam Pract"},{"issue":"6","key":"14149_CR47","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/bcpt.13859","volume":"133","author":"C McCarthy","year":"2023","unstructured":"McCarthy C, Flood M, Clyne B, Smith SM, Boland F, Wallace E, et al. Association between patient attitudes towards deprescribing and subsequent prescription changes. Basic Clin Pharmacol Toxicol. 2023;133(6):683\u2013690","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"14149_CR48","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1136\/ejhpharm-2017-001482","volume":"25","author":"N Barnett","year":"2018","unstructured":"Barnett N, Garfinkel D. Deprescribing one year on: challenging the first iatrogenic epidemic. Eur J Hosp Pharm: Sci Pract. Engl. 2018;25:63\u201364","journal-title":"Eur J Hosp Pharm: Sci Pract. Engl"},{"issue":"11","key":"14149_CR49","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1111\/bcp.15805","volume":"89","author":"J Kornholt","year":"2023","unstructured":"Kornholt J, Feizi ST, Hansen AS, Laursen JT, Johansson KS, Reuther L\u00d8, et al. Medication changes implemented during medication reviews and factors related to deprescribing: posthoc analyses of a randomized clinical trial in geriatric outpatients with polypharmacy. Br J Clin Pharmacol. 2023;89(11):3291\u20133301","journal-title":"Br J Clin Pharmacol"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-026-14149-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-14149-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-14149-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:21:48Z","timestamp":1781634108000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12913-026-14149-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["14149"],"URL":"https:\/\/doi.org\/10.1186\/s12913-026-14149-2","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"18 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was conducted throughout the enrolment process, briefly explained the aim of the study, that the participation was voluntary and they can withdraw from the study whenever they wish, without giving any explanation and without affecting their health care or their relationship with the professionals who care for them. Also explained the possible risks of the research and facilitates contact with the principal investigator. The study was registered at ClinicalTrials.gov NCT06209827.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This study has been approved by the Health Research Ethics Board of Hospitals Virgen Macarena-Virgen del Roc\u00edo (IFLBZD16).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"390"}}